Anti-CLEC2A Antibody, clone 8D2.1

C-type lectin domain family 2 member A (CLEC2A) is also called proliferation-induced lymphocyte-associated receptor (PILAR) and Keratinocyte-associated C-type lectin (KACL). CLEC2A is involved in modulating T-cell expansion. It is a 32 kDa single-pass type II membrane protein that belongs to the CTL/CTLD superfamily. CLEC2A is mainly expressed in skin and highly expressed in CD8(+), B lymphocytes and naive CD4(+) T cells. Modulation of CLEC2A signaling may be important for treatment of autoimmune diseases and cancer. CLEC2A is associated with expansion of TCR-stimulated T-cells, modulates the capacity of T-cells to home to lymph nodes through SELL, and facilitates immune recognition of keratinocytes by stimulating natural killer cell mediated cytotoxicity.

~18 kDa observed

Epitope: Extracellular domain

KLH-conjugated linear peptide corresponding to the extracellular domain of human CLEC2A.

Research Category
Apoptosis & Cancer

Research Sub Category
Apoptosis - Additional

This Anti-CLEC2A Antibody, clone 8D2.1 is validated for use in Western Blotting for the detection of CLEC2A.

Format: Purified

Protein G Purified

Purified mouse monoclonal IgG1κ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.

Evaluated by Western Blotting in Raji cell lysate.

Western Blotting Analysis: 1.0 µg/mL of this antibody detected CLEC2A in 200 µg of Raji cell lysate.

Concentration: Please refer to lot specific datasheet.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.